Yesterday, Aug. 18, 2015, 118 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $188.23 to $3,409,507.50.

Highlighted Stocks Traded by Insiders:

Annaly Capital Management (NLY) - FREE Research Report

Votek Glenn, who is Chief Financial Officer at Annaly Capital Management, bought 25,000 shares at $10.36 on Aug. 18, 2015. Following this transaction, the Chief Financial Officer owned 51,509 shares meaning that the stake was boosted by 94.31% with the 25,000-share transaction.

The shares most recently traded at $10.43, up $0.07, or 0.67% since the insider transaction. Historical insider transactions for Annaly Capital Management go as follows:

  • 4-Week # shares bought: 300,000
  • 12-Week # shares bought: 300,000
  • 24-Week # shares bought: 509,948

The average volume for Annaly Capital Management has been 10.7 million shares per day over the past 30 days. Annaly Capital Management has a market cap of $9.8 billion and is part of the financial sector and real estate industry. Shares are down 3.7% year-to-date as of the close of trading on Tuesday.

Annaly Capital Management, Inc. owns a portfolio of real estate related investments in the United States. The stock currently has a dividend yield of 11.57%. The company has a P/E ratio of 172.8. Currently, there are 2 analysts who rate Annaly Capital Management a buy, 3 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NLY - FREE

TheStreet Quant Ratings

rates Annaly Capital Management as a

hold

. The company's strengths can be seen in multiple areas, such as its increase in net income, expanding profit margins and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and disappointing return on equity. Get the full

Annaly Capital Management Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Natures Sunshine Products (NATR) - FREE Research Report

Probert Gregory, who is CEO & Chairman of the Board at Natures Sunshine Products, bought 6,648 shares at $12.98 on Aug. 18, 2015. Following this transaction, the CEO & Chairman of the Board owned 140,754 shares meaning that the stake was boosted by 4.96% with the 6,648-share transaction.

The shares most recently traded at $13.05, up $0.07, or 0.51% since the insider transaction. Historical insider transactions for Natures Sunshine Products go as follows:

  • 4-Week # shares bought: 6,470
  • 12-Week # shares bought: 16,274
  • 24-Week # shares bought: 55,670

The average volume for Natures Sunshine Products has been 32,000 shares per day over the past 30 days. Natures Sunshine Products has a market cap of $241.7 million and is part of the health care sector and drugs industry. Shares are down 12.42% year-to-date as of the close of trading on Tuesday.

Nature's Sunshine Products, Inc., together with its subsidiaries, primarily engages in the manufacture and direct sale of nutritional and personal care products worldwide. The stock currently has a dividend yield of 3.09%. The company has a P/E ratio of 215.5. Currently, there are no analysts who rate Natures Sunshine Products a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NATR - FREE

TheStreet Recommends

TheStreet Quant Ratings

rates Natures Sunshine Products as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and disappointing return on equity. Get the full

Natures Sunshine Products Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abiomed (ABMD) - FREE Research Report

Puhy Dorothy E, who is Director at Abiomed, sold 2,580 shares at $103.91 on Aug. 18, 2015. Following this transaction, the Director owned 62,190 shares meaning that the stake was reduced by 3.98% with the 2,580-share transaction.

The shares most recently traded at $104.77, up $0.86, or 0.82% since the insider transaction. Historical insider transactions for Abiomed go as follows:

  • 4-Week # shares bought: 7,500
  • 4-Week # shares sold: 9,778
  • 12-Week # shares bought: 7,500
  • 12-Week # shares sold: 34,258
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 143,519

The average volume for Abiomed has been 770,400 shares per day over the past 30 days. Abiomed has a market cap of $4.5 billion and is part of the health care sector and health services industry. Shares are up 175.7% year-to-date as of the close of trading on Tuesday.

ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company has a P/E ratio of 35.6. Currently, there are 4 analysts who rate Abiomed a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABMD - FREE

TheStreet Quant Ratings

rates Abiomed as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Abiomed Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.